Xeomin® for Post-Stroke Mobility
Trial Summary
What is the purpose of this trial?
This trial is testing whether Xeomin® injections can help adults with one-sided weakness walk better. The study will measure walking ability using two common tests. Xeomin® works by relaxing muscles, which may make it easier for these patients to move.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, you cannot have had botulinum toxin treatment in the past 4 months.
What data supports the effectiveness of the drug Xeomin® for improving mobility after a stroke?
Research shows that Xeomin® (incobotulinumtoxinA) is effective in reducing muscle stiffness (spasticity) in both upper and lower limbs after a stroke, which can help improve movement. Studies have demonstrated improvements in walking speed and reduction in pain, indicating better overall mobility.12345
Is Xeomin® safe for human use?
Xeomin® (incobotulinumtoxinA) has been shown to be generally safe for treating various conditions like spasticity, blepharospasm, and cervical dystonia. It is a purified form of botulinum toxin type A, and studies have found it to have good tolerability with no reported cases of therapy failure due to antibodies.12356
How is the drug Xeomin® unique for post-stroke mobility?
Xeomin® is unique because it is a purified form of botulinum toxin type A that is free from complexing proteins, which may reduce the risk of immune response and improve tolerability. It has shown effectiveness in treating spasticity (muscle stiffness) in both upper and lower limbs, which can help improve mobility after a stroke.12345
Eligibility Criteria
This trial is for adults who have had a stroke, resulting in hemiparesis and spasticity but can walk at least 10 meters unaided. They shouldn't have had surgery on the lower limb or botulinum toxin treatment within 4 months. Excluded are those with severe communication deficits, lack of body position sense, joint contractures, other major neurological conditions or acute illnesses, limited joint movement, hearing issues or unsafe weight-bearing.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Xeomin® injection into the upper limb and are evaluated using physical function tests
Follow-up
Participants are contacted for an end of study visit via telephone to obtain information regarding any adverse events and gain insight into the therapeutic duration of the Xeomin®
Treatment Details
Interventions
- Xeomin® (Neurotoxin)